EP2535349A1
(en)
|
2007-09-26 |
2012-12-19 |
UCB Pharma S.A. |
Dual specificity antibody fusions
|
US8242247B2
(en)
*
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
US9266967B2
(en)
*
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US10407513B2
(en)
|
2008-09-26 |
2019-09-10 |
Ucb Biopharma Sprl |
Biological products
|
MX338825B
(es)
|
2008-10-02 |
2016-05-03 |
Emergent Product Dev Seattle |
Proteinas de enlace a objetivos multiples de antagonistas de cd86.
|
US8268314B2
(en)
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
BRPI1014089A2
(pt)
*
|
2009-04-02 |
2016-04-19 |
Roche Glycart Ag |
anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
|
JP5616428B2
(ja)
|
2009-04-07 |
2014-10-29 |
ロシュ グリクアート アクチェンゲゼルシャフト |
三価の二重特異性抗体
|
SG176219A1
(en)
*
|
2009-05-27 |
2011-12-29 |
Hoffmann La Roche |
Tri- or tetraspecific antibodies
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
US8703132B2
(en)
*
|
2009-06-18 |
2014-04-22 |
Hoffmann-La Roche, Inc. |
Bispecific, tetravalent antigen binding proteins
|
US20120204278A1
(en)
|
2009-07-08 |
2012-08-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
HUE055817T2
(hu)
*
|
2009-07-08 |
2021-12-28 |
Kymab Ltd |
Állatmodellek és terápiás molekulák
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
NZ598962A
(en)
|
2009-09-16 |
2014-12-24 |
Genentech Inc |
Coiled coil and/or tether containing protein complexes and uses thereof
|
PT2519543T
(pt)
*
|
2009-12-29 |
2016-10-07 |
Emergent Product Dev Seattle |
Proteínas de ligação de heterodímero e suas utilizações
|
CN102712769B
(zh)
|
2010-01-29 |
2014-12-03 |
东丽株式会社 |
聚乳酸系树脂片
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
TWI426920B
(zh)
*
|
2010-03-26 |
2014-02-21 |
Hoffmann La Roche |
雙專一性、雙價抗-vegf/抗-ang-2抗體
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
KR20130055647A
(ko)
|
2010-07-19 |
2013-05-28 |
에프. 호프만-라 로슈 아게 |
항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
|
KR20130126576A
(ko)
|
2010-07-19 |
2013-11-20 |
에프. 호프만-라 로슈 아게 |
항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
JP2013541937A
(ja)
|
2010-08-05 |
2013-11-21 |
エフ.ホフマン−ラ ロシュ アーゲー |
抗mhc抗体−抗ウイルス性サイトカイン融合タンパク質
|
ES2537207T3
(es)
|
2010-08-16 |
2015-06-03 |
Novimmune S.A. |
Métodos para la generación de anticuerpos multiespecíficos y multivalentes
|
CA2807278A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann - La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
AU2011336410B2
(en)
|
2010-12-02 |
2015-01-22 |
Oncolytics Biotech Inc. |
Lyophilized viral formulations
|
WO2012075379A2
(en)
|
2010-12-02 |
2012-06-07 |
Oncolytics Biotech Inc. |
Liquid viral formulations
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
CA2824824A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Monovalent antigen binding proteins
|
MX341921B
(es)
|
2011-02-28 |
2016-09-07 |
Hoffmann La Roche |
Proteinas de union a antigeno.
|
RU2013150331A
(ru)
|
2011-04-20 |
2015-05-27 |
Рош Гликарт Аг |
СПОСОБ И УСТРОЙСТВА ДЛЯ рН-ЗАВИСИМОГО ПРОХОЖДЕНИЯ ГЕМАТОЭНЦЕФАЛИЧЕСКОГО БАРЬЕРА
|
JP6152090B2
(ja)
|
2011-04-21 |
2017-06-21 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate |
視神経脊髄炎を処置するための組成物および方法
|
EA201391605A1
(ru)
*
|
2011-04-29 |
2014-02-28 |
Онколитикс Байотек Инк. |
Способы очистки вирусов с использованием гельпроникающей хроматографии
|
WO2012171996A1
(en)
|
2011-06-15 |
2012-12-20 |
F. Hoffmann-La Roche Ag |
Anti-human epo receptor antibodies and methods of use
|
CN103649125A
(zh)
|
2011-06-22 |
2014-03-19 |
霍夫曼-拉罗奇有限公司 |
利用包含mhc i类的复合物通过循环中的病毒特异性细胞毒性t细胞清除靶细胞
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
RU2605390C2
(ru)
*
|
2011-08-23 |
2016-12-20 |
Рош Гликарт Аг |
Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
|
WO2013026837A1
(en)
*
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
KR101723273B1
(ko)
*
|
2011-08-23 |
2017-04-04 |
로슈 글리카트 아게 |
2 개의 fab 단편을 포함하는 fc-부재 항체 및 이용 방법
|
EP2748202B1
(en)
*
|
2011-08-23 |
2018-07-04 |
Roche Glycart AG |
Bispecific antigen binding molecules
|
JP6339015B2
(ja)
*
|
2011-08-23 |
2018-06-06 |
ロシュ グリクアート アーゲー |
二重特異性t細胞活性化抗原結合分子
|
CA2846319A1
(en)
|
2011-09-19 |
2013-03-28 |
Kymab Limited |
Antibodies, variable domains & chains tailored for human use
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
CA2853230C
(en)
|
2011-10-31 |
2021-11-23 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
RU2633488C2
(ru)
|
2011-12-19 |
2017-10-12 |
Ф. Хоффманн-Ля Рош Аг |
Способ определения свободного связывающего партнера мультиспецифичного связующего
|
BR112014013035A2
(pt)
|
2011-12-22 |
2018-10-09 |
Hoffmann La Roche |
métodos de seleção de células, conjuntos de expressão bicistrônica, células eucarióticas, vetores lentivirais, uso de vetor lentiviral, bibliotecas de ventores lentivirais e de células eucarióticas, métodos de seleção de células, fluxos de trabalho e uso de célula
|
EP3354660A1
(en)
|
2011-12-22 |
2018-08-01 |
F. Hoffmann-La Roche AG |
Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
|
SG10201601882PA
(en)
|
2011-12-22 |
2016-04-28 |
Hoffmann La Roche |
Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of Polypeptides
|
MX349661B
(es)
|
2012-02-01 |
2017-08-08 |
Hoffmann La Roche |
Metodo para la deteccion de una molecula de union de un enlazador multiespecifico.
|
EP2809682B1
(en)
|
2012-02-03 |
2020-04-08 |
F.Hoffmann-La Roche Ag |
Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine
|
WO2013119966A2
(en)
|
2012-02-10 |
2013-08-15 |
Genentech, Inc. |
Single-chain antibodies and other heteromultimers
|
TR201808458T4
(tr)
|
2012-02-15 |
2018-07-23 |
Hoffmann La Roche |
FC-reseptör bazlı afinite kromatografisi.
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
BR112014025830A8
(pt)
|
2012-04-20 |
2017-10-10 |
Emergent Product Dev Seattle |
Polipeptídeos de ligação ao cd3
|
US9062120B2
(en)
|
2012-05-02 |
2015-06-23 |
Janssen Biotech, Inc. |
Binding proteins having tethered light chains
|
WO2013164325A1
(en)
*
|
2012-05-02 |
2013-11-07 |
F. Hoffmann-La Roche Ag |
Multispecific antigen binding proteins
|
KR20150013188A
(ko)
|
2012-05-24 |
2015-02-04 |
에프. 호프만-라 로슈 아게 |
다중특이적 항체
|
EP2867253B1
(en)
|
2012-06-27 |
2016-09-14 |
F. Hoffmann-La Roche AG |
Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
|
BR112014028368A2
(pt)
|
2012-06-27 |
2017-11-14 |
Hoffmann La Roche |
método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
|
CN104394886B
(zh)
|
2012-07-04 |
2017-05-24 |
弗·哈夫曼-拉罗切有限公司 |
抗茶碱抗体及使用方法
|
EP3339328A1
(en)
|
2012-07-04 |
2018-06-27 |
F. Hoffmann-La Roche AG |
Anti-biotin antibodies and methods of use
|
EP2869848B1
(en)
|
2012-07-04 |
2016-09-21 |
F. Hoffmann-La Roche AG |
Covalently linked antigen-antibody conjugates
|
HUE056217T2
(hu)
|
2012-07-13 |
2022-02-28 |
Roche Glycart Ag |
Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében
|
KR20150038046A
(ko)
|
2012-07-13 |
2015-04-08 |
에프. 호프만-라 로슈 아게 |
다중특이적 결합체의 탐지 방법
|
KR101963231B1
(ko)
|
2012-09-11 |
2019-03-28 |
삼성전자주식회사 |
이중특이 항체의 제작을 위한 단백질 복합체 및 이를 이용한 이중특이 항체 제조 방법
|
RU2646159C2
(ru)
|
2012-09-14 |
2018-03-01 |
Ф. Хоффманн-Ля Рош Аг |
Способ получения и отбора молекул, включающих по меньшей мере две различные группировки, и их применение
|
BR112015007120A2
(pt)
*
|
2012-10-08 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
|
WO2014072306A1
(en)
|
2012-11-08 |
2014-05-15 |
F. Hoffmann-La Roche Ag |
Her3 antigen binding proteins binding to the beta-hairpin of her3
|
EP2953974B1
(en)
|
2013-02-05 |
2017-12-20 |
EngMab Sàrl |
Bispecific antibodies against cd3epsilon and bcma
|
EP2762497A1
(en)
*
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
MX2015010843A
(es)
*
|
2013-02-26 |
2016-04-04 |
Roche Glycart Ag |
Moleculas biespecificas de union al antigeno que activan celulas t.
|
KR101833602B1
(ko)
|
2013-02-26 |
2018-02-28 |
로슈 글리카트 아게 |
이중특이적 t 세포 활성화 항원 결합 분자
|
RU2015140915A
(ru)
*
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
MY172430A
(en)
|
2013-04-29 |
2019-11-25 |
Hoffmann La Roche |
Human fcrn-binding modified antibodies and methods of use
|
EP3327034A1
(en)
|
2013-04-29 |
2018-05-30 |
F. Hoffmann-La Roche AG |
Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
|
EP2992010B1
(en)
|
2013-04-29 |
2021-03-24 |
F.Hoffmann-La Roche Ag |
Fc-receptor binding modified asymmetric antibodies and methods of use
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
US9879081B2
(en)
|
2013-06-25 |
2018-01-30 |
Samsung Electronics Co., Ltd. |
Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
|
WO2015025054A1
(en)
|
2013-08-22 |
2015-02-26 |
Medizinische Universität Wien |
Dye-specific antibodies for prestained molecular weight markers and methods producing the same
|
RU2758952C1
(ru)
|
2013-09-27 |
2021-11-03 |
Чугаи Сейяку Кабусики Кайся |
Способ получения полипептидного гетеромультимера
|
TW201546284A
(zh)
|
2013-10-01 |
2015-12-16 |
Kymab Ltd |
動物模式及治療分子
|
BR112016006929A2
(pt)
*
|
2013-10-11 |
2017-09-19 |
Hoffmann La Roche |
Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
|
NZ717673A
(en)
|
2013-11-21 |
2020-02-28 |
Hoffmann La Roche |
Anti-alpha-synuclein antibodies and methods of use
|
CN105899533B
(zh)
|
2013-12-20 |
2019-10-11 |
豪夫迈·罗氏有限公司 |
人源化的抗-Tau(pS422)抗体和使用方法
|
RU2016129517A
(ru)
|
2013-12-20 |
2018-01-25 |
Ф. Хоффманн-Ля Рош Аг |
Биспецифические антитела к her2 и способы применения
|
MX2016008191A
(es)
|
2014-01-03 |
2017-11-16 |
Hoffmann La Roche |
Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente.
|
BR112016012666A2
(pt)
|
2014-01-03 |
2017-09-26 |
Hoffmann La Roche |
conjugado, anticorpos, formulação farmacêutica e usos de conjugado
|
JP6476194B2
(ja)
|
2014-01-03 |
2019-02-27 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
二重特異性抗ハプテン/抗血液脳関門受容体抗体、それらの複合体、及び血液脳関門シャトルとしてのそれらの使用
|
RU2694659C2
(ru)
|
2014-01-06 |
2019-07-16 |
Ф. Хоффманн-Ля Рош Аг |
Одновалентные модули-переносчики через гематоэнцефалический барьер
|
EP3835318A1
(en)
|
2014-01-15 |
2021-06-16 |
F. Hoffmann-La Roche AG |
Fc-region variants with modified fcrn- and maintained protein a-binding properties
|
EP3842455A1
(en)
|
2014-01-15 |
2021-06-30 |
F. Hoffmann-La Roche AG |
Fc-region variants with improved protein a-binding
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
EP3725812B1
(en)
*
|
2014-03-03 |
2023-09-27 |
Academia Sinica |
Bi-specific antibodies and uses thereof
|
EP3116909B1
(en)
|
2014-03-14 |
2019-11-13 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
SG11201608054YA
(en)
|
2014-04-02 |
2016-10-28 |
Hoffmann La Roche |
Method for detecting multispecific antibody light chain mispairing
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
US10329556B2
(en)
|
2014-05-13 |
2019-06-25 |
Bioatla, Llc |
Conditionally active biological proteins
|
KR102433464B1
(ko)
|
2014-05-28 |
2022-08-17 |
아게누스 인코포레이티드 |
항-gitr 항체 및 이의 사용 방법
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
EP3164419A1
(en)
|
2014-06-26 |
2017-05-10 |
F. Hoffmann-La Roche AG |
Anti-brdu antibodies and methods of use
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
AU2015283704A1
(en)
|
2014-07-01 |
2016-12-15 |
Pfizer Inc. |
Bispecific heterodimeric diabodies and uses thereof
|
WO2016005545A1
(en)
|
2014-07-10 |
2016-01-14 |
Affiris Ag |
Substances and methods for the use in prevention and/or treatment in huntington's disease
|
AU2015286569B2
(en)
|
2014-07-11 |
2021-04-15 |
Genmab A/S |
Antibodies binding AXL
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
CN112481283A
(zh)
|
2014-07-21 |
2021-03-12 |
诺华股份有限公司 |
使用cd33嵌合抗原受体治疗癌症
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-bcma嵌合抗原受體治療癌症
|
EP3174546B1
(en)
|
2014-07-31 |
2019-10-30 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
MA40510A
(fr)
|
2014-08-04 |
2017-06-14 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
JP6919118B2
(ja)
|
2014-08-14 |
2021-08-18 |
ノバルティス アーゲー |
GFRα−4キメラ抗原受容体を用いる癌の治療
|
MY189028A
(en)
|
2014-08-19 |
2022-01-20 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
AU2015317608B2
(en)
|
2014-09-17 |
2021-03-11 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
JP6708635B2
(ja)
|
2014-10-09 |
2020-06-10 |
エンクマフ エスアーエールエル |
CD3εおよびROR1に対する二特異性抗体
|
EP4245376A3
(en)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
BR112017006591A2
(pt)
|
2014-11-06 |
2018-01-16 |
Hoffmann La Roche |
polipeptídeo heterodimérico, formulação farmacêutica e uso de um polipeptídeo heterodimérico
|
WO2016071376A2
(en)
|
2014-11-06 |
2016-05-12 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn-binding and methods of use
|
ES2835823T3
(es)
|
2014-11-20 |
2021-06-23 |
Hoffmann La Roche |
Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T para CD3 y para el receptor de folato 1 (FolR1) y antagonistas de la unión al eje de PD-1
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
EP3227341A1
(en)
|
2014-12-02 |
2017-10-11 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
|
WO2016090034A2
(en)
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
EP3029137B1
(en)
|
2014-12-06 |
2019-01-02 |
GEMoaB Monoclonals GmbH |
Genetic modified pluri- or multipotent stem cells and uses thereof
|
EP3633371A1
(en)
|
2014-12-18 |
2020-04-08 |
F. Hoffmann-La Roche AG |
Assay and method for determining cdc eliciting antibodies
|
EP3789039A1
(en)
|
2014-12-22 |
2021-03-10 |
The Rockefeller University |
Anti-mertk agonistic antibodies and uses thereof
|
CN107667120B
(zh)
|
2015-03-17 |
2022-03-08 |
纪念斯隆-凯特林癌症中心 |
抗muc16抗体及其应用
|
SI3280729T1
(sl)
|
2015-04-08 |
2022-09-30 |
Novartis Ag |
Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR)
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
KR102668727B1
(ko)
|
2015-04-24 |
2024-05-28 |
제넨테크, 인크. |
다중특이적 항원-결합 단백질
|
US10144779B2
(en)
|
2015-05-29 |
2018-12-04 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
WO2016207245A1
(en)
|
2015-06-24 |
2016-12-29 |
F. Hoffmann-La Roche Ag |
Humanized anti-tau(ps422) antibodies and methods of use
|
EP3319993B1
(en)
|
2015-07-10 |
2020-01-15 |
Genmab A/S |
Axl-specific antibody-drug conjugates for cancer treatment
|
IL256562B1
(en)
|
2015-07-15 |
2024-03-01 |
Genmab As |
Human CD3 antibodies or chimeras
|
LT3317301T
(lt)
|
2015-07-29 |
2021-07-26 |
Novartis Ag |
Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
IL297090A
(en)
|
2015-07-30 |
2022-12-01 |
Macrogenics Inc |
Molecules that bind pd-1 and methods of using them
|
US10323091B2
(en)
|
2015-09-01 |
2019-06-18 |
Agenus Inc. |
Anti-PD-1 antibodies and methods of use thereof
|
US11352426B2
(en)
|
2015-09-21 |
2022-06-07 |
Aptevo Research And Development Llc |
CD3 binding polypeptides
|
ES2906823T3
(es)
|
2015-09-30 |
2022-04-20 |
Janssen Biotech Inc |
Anticuerpos agonistas que se unen específicamente a CD40 humano y métodos de uso
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
WO2017055395A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
WO2017055318A1
(en)
*
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Cd33xcd3 bispecific t cell activating antigen binding molecules
|
CN108139394B
(zh)
|
2015-10-02 |
2020-10-30 |
豪夫迈·罗氏有限公司 |
用于确定同时结合的基于细胞的fret测定法
|
US20170096495A1
(en)
|
2015-10-02 |
2017-04-06 |
Hoffmann-La Roche Inc. |
Bispecific t cell activating antigen binding molecules
|
CN108026179A
(zh)
|
2015-10-02 |
2018-05-11 |
豪夫迈·罗氏有限公司 |
结合间皮素和cd3的双特异性t细胞活化性抗原结合分子
|
EP3150637A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Multispecific antibodies
|
EP3356407B1
(en)
|
2015-10-02 |
2021-11-03 |
F. Hoffmann-La Roche AG |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
EP3150636A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
EP3356404B1
(en)
|
2015-10-02 |
2021-08-18 |
F. Hoffmann-La Roche AG |
Anti-pd1 antibodies and methods of use
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
BR112018000835A2
(pt)
*
|
2015-10-02 |
2018-09-11 |
Hoffmann La Roche |
molécula, um ou mais polinucleotídeos, um ou mais vetores, célula, método de produção da molécula, composição, uso da molécula, método de tratamento de uma doença e método para induzir a lise de uma célula-alvo
|
KR20180069065A
(ko)
|
2015-10-29 |
2018-06-22 |
에프. 호프만-라 로슈 아게 |
항-변이체 fc-부위 항체 및 사용 방법
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
MA43186B1
(fr)
|
2015-11-03 |
2022-03-31 |
Janssen Biotech Inc |
Anticorps se liant spécifiquement à pd-1 et leurs utilisations
|
PL3387015T3
(pl)
|
2015-12-09 |
2022-02-14 |
F. Hoffmann-La Roche Ag |
Przeciwciało anty-CD20 typu II do ograniczania tworzenia przeciwciał przeciwlekowych
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
TWI758267B
(zh)
|
2015-12-14 |
2022-03-21 |
美商宏觀基因股份有限公司 |
對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
|
US20200261573A1
(en)
|
2015-12-17 |
2020-08-20 |
Novartis Ag |
Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
|
MX2018007423A
(es)
|
2015-12-17 |
2018-11-09 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
|
CA3006529A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
WO2017149515A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
JP7082604B2
(ja)
|
2016-03-21 |
2022-06-08 |
マレンゴ・セラピューティクス,インコーポレーテッド |
多重特異性および多機能性分子ならびにその使用
|
PE20231511A1
(es)
|
2016-03-22 |
2023-09-26 |
Hoffmann La Roche |
Moleculas biespecificas de celulas t activadas por proteasas que se unen especificamente al receptor 1 de folato (folr1) y cd3
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
BR112018071096A2
(pt)
|
2016-04-15 |
2019-02-26 |
Novartis Ag |
composições e métodos para a expressão da proteína seletiva
|
UA123323C2
(uk)
|
2016-05-02 |
2021-03-17 |
Ф. Хоффманн-Ля Рош Аг |
Димерний злитий поліпептид
|
MX2018014047A
(es)
|
2016-05-17 |
2019-06-20 |
Genentech Inc |
Firmas de genes estromales para el diagnóstico y uso en inmunoterapia.
|
SG10201912563XA
(en)
|
2016-05-27 |
2020-02-27 |
Agenus Inc |
Anti-tim-3 antibodies and methods of use thereof
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
BR112019022558A2
(pt)
|
2016-06-02 |
2020-05-19 |
Hoffmann La Roche |
anticorpos, métodos para tratar ou retardar a progressão de uma doença proliferativa e para tratar ou retardar a progressão do câncer em um indivíduo, composições farmacêuticas, kit, usos de uma combinação de um anticorpo anti-cd20 e de um anticorpo e invenção
|
US20210177896A1
(en)
|
2016-06-02 |
2021-06-17 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
AR108800A1
(es)
|
2016-06-17 |
2018-09-26 |
Genentech Inc |
Purificación de anticuerpos multiespecíficos
|
JP2019525772A
(ja)
|
2016-07-08 |
2019-09-12 |
スターテン・バイオテクノロジー・ベー・フェー |
抗apoc3抗体およびその使用方法
|
JP2019532017A
(ja)
|
2016-07-14 |
2019-11-07 |
フレッド ハッチンソン キャンサー リサーチ センター |
がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物
|
BR112019000512A2
(pt)
|
2016-07-14 |
2019-04-24 |
Genmab A/S |
anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
|
US20190336504A1
(en)
|
2016-07-15 |
2019-11-07 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
KR20230100748A
(ko)
|
2016-07-28 |
2023-07-05 |
노파르티스 아게 |
키메라 항원 수용체 및 pd-1 억제제의 조합 요법
|
MX2019001469A
(es)
|
2016-08-01 |
2019-10-02 |
Novartis Ag |
Tratamiento del cáncer usando un receptor de antígeno quimérico en combinación con un inhibidor de una molécula de macrófago pro- m2.
|
JP7178342B2
(ja)
|
2016-08-12 |
2022-11-25 |
ヤンセン バイオテツク,インコーポレーテツド |
アゴニズム及びエフェクター機能が増強した改変抗体、及び他のFcドメイン含有分子
|
CA3033665A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
JP6976315B2
(ja)
|
2016-09-19 |
2021-12-08 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
補体因子に基づくアフィニティークロマトグラフィー
|
CN109791149A
(zh)
|
2016-09-30 |
2019-05-21 |
豪夫迈·罗氏有限公司 |
用于功能分析多特异性分子的基于spr的双重结合测定法
|
ES2897217T3
(es)
|
2016-09-30 |
2022-02-28 |
Hoffmann La Roche |
Anticuerpos biespecíficos frente a p95HER2
|
TW202340473A
(zh)
|
2016-10-07 |
2023-10-16 |
瑞士商諾華公司 |
利用嵌合抗原受體之癌症治療
|
KR20230133934A
(ko)
|
2016-10-11 |
2023-09-19 |
아게누스 인코포레이티드 |
항-lag-3 항체 및 이의 사용 방법
|
KR102431830B1
(ko)
|
2016-11-07 |
2022-08-16 |
주식회사 뉴라클사이언스 |
서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
BR112019010349A2
(pt)
|
2016-11-23 |
2019-10-08 |
Bioverativ Therapeutics Inc |
Anticorpos anti-fixa, anti-fxz e antifxa, molécula biespecífica, ácido nulceico, composiçãofarmacêutica e uso dos anteriores
|
MX2019006340A
(es)
|
2016-12-07 |
2019-11-07 |
Agenus Inc |
Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos.
|
EP3554542A1
(en)
|
2016-12-19 |
2019-10-23 |
H. Hoffnabb-La Roche Ag |
Combination therapy with targeted 4-1bb (cd137) agonists
|
PL3559034T3
(pl)
|
2016-12-20 |
2021-04-19 |
F. Hoffmann-La Roche Ag |
Terapia skojarzona dwuswoistymi przeciwciałami anty-CD20/anty-CD3 i agonistami 4-1BB (CD137)
|
CA3044920C
(en)
|
2016-12-21 |
2022-06-28 |
Roberto Falkenstein |
In vitro glycoengineering of antibodies
|
CA3043158A1
(en)
|
2016-12-21 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Re-use of enzymes in in vitro glycoengineering of antibodies
|
AU2017381657B2
(en)
|
2016-12-21 |
2020-07-23 |
F. Hoffmann-La Roche Ag |
Method for in vitro glycoengineering of antibodies
|
WO2018140725A1
(en)
|
2017-01-26 |
2018-08-02 |
Novartis Ag |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
US20200048359A1
(en)
|
2017-02-28 |
2020-02-13 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
EP3592769B1
(en)
|
2017-03-09 |
2024-05-08 |
Genmab A/S |
Antibodies against pd-l1
|
JP7021245B2
(ja)
|
2017-03-10 |
2022-02-16 |
エフ.ホフマン-ラ ロシュ アーゲー |
多重特異性抗体を生産するための方法
|
US11235056B2
(en)
|
2017-03-24 |
2022-02-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Glycan-masked engineered outer domains of HIV-1 gp120 and their use
|
MX2019011624A
(es)
|
2017-03-27 |
2019-12-05 |
Celgene Corp |
Metodos y composiciones para la reduccion de la inmunogenicidad.
|
CA3057907A1
(en)
|
2017-03-31 |
2018-10-04 |
Genmab Holding B.V. |
Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
|
KR102629972B1
(ko)
|
2017-04-13 |
2024-01-29 |
아게누스 인코포레이티드 |
항-cd137 항체 및 이의 사용 방법
|
WO2018193427A1
(en)
|
2017-04-21 |
2018-10-25 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
MA50957A
(fr)
|
2017-05-01 |
2020-10-14 |
Agenus Inc |
Anticorps anti-tigit et leurs méthodes d'utilisation
|
WO2018210898A1
(en)
|
2017-05-18 |
2018-11-22 |
F. Hoffmann-La Roche Ag |
Reduction of application-related side reaction of a therapeutic antibody
|
EP3630836A1
(en)
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
CA3065516A1
(en)
|
2017-06-05 |
2018-12-13 |
Janssen Biotech, Inc. |
Antibodies that specifically bind pd-1 and methods of use
|
CN111328335A
(zh)
|
2017-06-07 |
2020-06-23 |
根马布私人有限公司 |
基于突变igg六聚体的治疗性抗体
|
PE20200717A1
(es)
|
2017-06-22 |
2020-07-21 |
Novartis Ag |
Moleculas de anticuerpo que se unen a cd73 y usos de las mismas
|
EP3645037A1
(en)
|
2017-06-27 |
2020-05-06 |
Novartis AG |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
JP2020526584A
(ja)
|
2017-06-28 |
2020-08-31 |
ザ ロックフェラー ユニバーシティー |
抗mertkアゴニスト抗体−薬物コンジュゲートおよびその使用
|
KR20200035966A
(ko)
|
2017-07-11 |
2020-04-06 |
콤파스 테라퓨틱스 엘엘씨 |
인간 cd137에 결합하는 작동자 항체 및 이의 용도
|
WO2019011167A1
(zh)
*
|
2017-07-12 |
2019-01-17 |
四川科伦博泰生物医药股份有限公司 |
双特异性重组蛋白
|
US20200172617A1
(en)
|
2017-07-20 |
2020-06-04 |
Novartis Ag |
Dosage regimens of anti-lag-3 antibodies and uses thereof
|
SG11202000198QA
(en)
|
2017-08-04 |
2020-02-27 |
Genmab As |
Binding agents binding to pd-l1 and cd137 and use thereof
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
CA3071236A1
(en)
|
2017-09-29 |
2019-04-04 |
Chugai Seiyaku Kabushiki Kaisha |
Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
|
EP3697441B1
(en)
|
2017-10-20 |
2023-06-07 |
F. Hoffmann-La Roche AG |
Method for generating multispecific antibodies from monospecific antibodies
|
BR112020007736A2
(pt)
|
2017-10-30 |
2020-10-20 |
F. Hoffmann-La Roche Ag |
composição e método de tratamento
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
WO2019089798A1
(en)
|
2017-10-31 |
2019-05-09 |
Novartis Ag |
Anti-car compositions and methods
|
MA50516A
(fr)
|
2017-10-31 |
2020-09-09 |
Staten Biotechnology B V |
Anticorps anti-apoc3 et leurs procédés d'utilisation
|
AU2018359506A1
(en)
|
2017-11-01 |
2020-04-23 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted OX40 agonists
|
MX2020004756A
(es)
|
2017-11-16 |
2020-08-20 |
Novartis Ag |
Terapias de combinacion.
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
JP7161534B2
(ja)
|
2017-11-29 |
2022-10-26 |
エフ.ホフマン-ラ ロシュ アーゲー |
標的による干渉が抑制された抗薬物抗体アッセイ
|
CN111491951B
(zh)
|
2017-12-22 |
2024-05-24 |
豪夫迈·罗氏有限公司 |
通过疏水相互作用色谱法耗尽轻链错配的抗体变体
|
SG11202006410WA
(en)
|
2018-01-12 |
2020-08-28 |
Genzyme Corp |
Methods for the quantitation of polypeptides
|
AU2019215031A1
(en)
|
2018-01-31 |
2020-08-20 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
AR115360A1
(es)
|
2018-02-08 |
2021-01-13 |
Genentech Inc |
Moléculas de unión al antígeno y métodos de uso
|
BR112020018490A2
(pt)
|
2018-03-12 |
2020-12-29 |
Genmab A/S |
Anticorpo, imunoconjugado ou conjugado de anticorpo-fármaco, construção de ácido nucléico, vetor de expressão, célula, composição, composição farmacêutica, anticorpo, método, método para produzir um anticorpo, kit de partes, e, anticorpo anti-idiotípico
|
CN111655731A
(zh)
|
2018-03-13 |
2020-09-11 |
豪夫迈·罗氏有限公司 |
用靶向性4-1bb(cd137)激动剂的组合疗法
|
AU2019236372B2
(en)
|
2018-03-13 |
2024-06-20 |
F. Hoffmann-La Roche Ag |
Therapeutic combination of 4-1 BB agonists with anti-CD20 antibodies
|
US20210009711A1
(en)
|
2018-03-14 |
2021-01-14 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
CN112119091A
(zh)
|
2018-05-10 |
2020-12-22 |
纽洛可科学有限公司 |
抗序列相似家族19成员a5的抗体及其使用方法
|
WO2019219721A1
(en)
|
2018-05-18 |
2019-11-21 |
F. Hoffmann-La Roche Ag |
Targeted intracellular delivery of large nucleic acids
|
CA3099308A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
MX2020012589A
(es)
|
2018-05-24 |
2021-01-29 |
Janssen Biotech Inc |
Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos.
|
SG11202011633SA
(en)
|
2018-05-24 |
2020-12-30 |
Janssen Biotech Inc |
Psma binding agents and uses thereof
|
SG11202011270QA
(en)
|
2018-05-24 |
2020-12-30 |
Janssen Biotech Inc |
Anti-cd3 antibodies and uses thereof
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
CN112243444A
(zh)
|
2018-06-08 |
2021-01-19 |
豪夫迈·罗氏有限公司 |
具有减少的翻译后修饰的肽接头
|
KR20210020932A
(ko)
|
2018-06-13 |
2021-02-24 |
노파르티스 아게 |
Bcma 키메라 항원 수용체 및 이의 용도
|
PE20210418A1
(es)
|
2018-06-19 |
2021-03-08 |
Atarga Llc |
Moleculas de anticuerpo de componente de complemento 5 y sus usos
|
EP3841124A4
(en)
|
2018-06-29 |
2022-03-23 |
ApitBio, Inc. |
ANTI-L1CAM ANTIBODIES AND THEIR USES
|
EP3818083A2
(en)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
SG11202100746WA
(en)
|
2018-07-25 |
2021-03-30 |
Innovent Biologics Suzhou Co Ltd |
Anti-tigit antibody and use thereof
|
CA3051549A1
(en)
|
2018-08-09 |
2020-02-09 |
Regeneron Pharmaceuticals, Inc. |
Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor
|
US20210371525A1
(en)
|
2018-09-19 |
2021-12-02 |
Lava Therapeutics B.V. |
Novel bispecific antibodies for use in the treatment of hematological malignancies
|
JP2022504287A
(ja)
|
2018-10-03 |
2022-01-13 |
スターテン・バイオテクノロジー・ベー・フェー |
ヒト及びカニクイザルapoc3に特異的な抗体、並びにその使用の方法
|
KR20210116429A
(ko)
|
2018-10-04 |
2021-09-27 |
젠맵 홀딩 비.브이. |
이중특이적 항-cd37 항체를 포함하는 제약 조성물
|
JP7208380B2
(ja)
|
2018-10-26 |
2023-01-18 |
エフ.ホフマン-ラ ロシュ アーゲー |
リコンビナーゼ媒介性カセット交換を使用した多重特異性抗体スクリーニング法
|
JP2022512875A
(ja)
|
2018-11-06 |
2022-02-07 |
ゲンマブ エー/エス |
抗体製剤
|
AU2019379576A1
(en)
|
2018-11-13 |
2021-06-03 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
CN109633053B
(zh)
*
|
2018-12-19 |
2021-04-30 |
杭州奕安济世生物药业有限公司 |
细胞培养物蛋白质表达量和蛋白质聚集体量的检测方法
|
WO2020128892A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Extended low dose regimens for mdm2 inhibitors
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
CN113227789A
(zh)
|
2018-12-30 |
2021-08-06 |
豪夫迈·罗氏有限公司 |
基于pH梯度SPR的结合测定
|
NL2022494B1
(en)
|
2019-02-01 |
2020-08-19 |
Lava Therapeutics B V |
Novel CD40-binding antibodies
|
WO2020159368A1
(en)
|
2019-02-01 |
2020-08-06 |
Lava Therapeutics B.V. |
Novel cd40-binding antibodies
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
US20220144807A1
(en)
|
2019-02-15 |
2022-05-12 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
JP2022522662A
(ja)
|
2019-02-21 |
2022-04-20 |
マレンゴ・セラピューティクス,インコーポレーテッド |
T細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
|
CA3130754A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
JP2022521750A
(ja)
|
2019-02-21 |
2022-04-12 |
マレンゴ・セラピューティクス,インコーポレーテッド |
カルレティキュリンに結合する多機能性分子およびその使用
|
CA3131014A1
(en)
|
2019-02-21 |
2020-08-27 |
Andreas Loew |
Anti-tcr antibody molecules and uses thereof
|
CA3130508A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
WO2020172553A1
(en)
|
2019-02-22 |
2020-08-27 |
Novartis Ag |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
JP2022521610A
(ja)
|
2019-02-26 |
2022-04-11 |
ヤンセン バイオテツク,インコーポレーテツド |
二重特異性抗egfr/c-met抗体による併用療法及び患者層別化
|
EP4378958A2
(en)
|
2019-02-26 |
2024-06-05 |
Inspirna, Inc. |
High-affinity anti-mertk antibodies and uses thereof
|
AU2020253833A1
(en)
|
2019-03-29 |
2021-10-28 |
Atarga, Llc |
Anti FGF23 antibody
|
JP7412440B2
(ja)
|
2019-03-29 |
2024-01-12 |
エフ. ホフマン-ラ ロシュ アーゲー |
アビド結合多重特異性抗体を作製する方法
|
EP3948281A1
(en)
|
2019-03-29 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Spr-based binding assay for the functional analysis of multivalent molecules
|
AR118720A1
(es)
|
2019-04-19 |
2021-10-27 |
Janssen Biotech Inc |
Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
|
PE20220763A1
(es)
|
2019-05-08 |
2022-05-16 |
Janssen Biotech Inc |
Materiales y metodos para modular la inmunidad mediada por celulas t
|
EP3969907A1
(en)
|
2019-05-13 |
2022-03-23 |
F. Hoffmann-La Roche AG |
Interference-suppressed pharmacokinetic immunoassay
|
JOP20210304A1
(ar)
|
2019-05-14 |
2023-01-30 |
Janssen Biotech Inc |
علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
|
AU2020296247A1
(en)
|
2019-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
KR20220010549A
(ko)
|
2019-06-19 |
2022-01-25 |
에프. 호프만-라 로슈 아게 |
정의된 조직에서 다중 발현 카세트의 표적화된 통합에 의해 다가 이중특이성 항체 발현 세포를 생성하는 방법
|
BR112021025425A2
(pt)
|
2019-06-19 |
2022-02-01 |
Hoffmann La Roche |
Método para produzir uma célula de mamífero recombinante e uso de mrna de recombinase cre
|
AU2020294878A1
(en)
|
2019-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
KR20220010019A
(ko)
|
2019-06-19 |
2022-01-25 |
에프. 호프만-라 로슈 아게 |
정의된 조직에서 다중 발현 카세트의 표적화된 통합에 의해 2가 이중특이성 항체 발현 세포를 생성하는 방법
|
KR20220016957A
(ko)
|
2019-06-26 |
2022-02-10 |
에프. 호프만-라 로슈 아게 |
Sirt-1 유전자 녹아웃을 갖는 포유류 세포주
|
US11680098B2
(en)
|
2019-08-30 |
2023-06-20 |
Agenus Inc. |
Antibodies that specifically bind human CD96
|
EP3792283A1
(en)
|
2019-09-16 |
2021-03-17 |
Lava Therapeutics B.V. |
Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
|
WO2021079195A1
(en)
|
2019-10-21 |
2021-04-29 |
Novartis Ag |
Tim-3 inhibitors and uses thereof
|
BR112022007376A2
(pt)
|
2019-10-21 |
2022-07-05 |
Novartis Ag |
Terapias de combinação com venetoclax e inibidores de tim-3
|
WO2021101346A1
(en)
*
|
2019-11-21 |
2021-05-27 |
Dong-A St Co., Ltd. |
Anti-ror1/anti-4-1bb bispecific antibodies and uses thereof
|
EP4065158A2
(en)
|
2019-11-26 |
2022-10-05 |
Novartis AG |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
WO2021123996A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
WO2021136772A1
(en)
|
2020-01-02 |
2021-07-08 |
F. Hoffmann-La Roche Ag |
Method for determining the amount of a therapeutic antibody in the brain
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
CD33-BINDING MULTIFUNCTIONAL MOLECULES AND THEIR USES
|
JP2023510393A
(ja)
|
2020-01-17 |
2023-03-13 |
ノバルティス アーゲー |
骨髄異形成症候群または慢性骨髄単球性白血病の処置に使用するためのtim-3阻害剤と低メチル化剤とを含む組合せ
|
EP4090762A1
(en)
|
2020-01-17 |
2022-11-23 |
Becton, Dickinson and Company |
Methods and compositions for single cell secretomics
|
WO2021155916A1
(en)
|
2020-02-04 |
2021-08-12 |
BioNTech SE |
Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
|
EP4110377A2
(en)
|
2020-02-27 |
2023-01-04 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
US20230126689A1
(en)
|
2020-03-06 |
2023-04-27 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
AR121599A1
(es)
|
2020-03-18 |
2022-06-22 |
Genmab As |
Anticuerpos
|
KR20230028242A
(ko)
|
2020-04-24 |
2023-02-28 |
마렝고 테라퓨틱스, 인크. |
T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
|
AU2021294222A1
(en)
|
2020-06-16 |
2023-01-19 |
F. Hoffmann-La Roche Ag |
Method for determining the free antigen of an antibody in a sample
|
CN115916825A
(zh)
|
2020-06-19 |
2023-04-04 |
豪夫迈·罗氏有限公司 |
与cd3和cd19结合的抗体
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
EP4178981A1
(en)
|
2020-07-08 |
2023-05-17 |
LAVA Therapeutics N.V. |
Antibodies that bind psma and gamma-delta t cell receptors
|
IL299586A
(en)
|
2020-07-16 |
2023-03-01 |
Novartis Ag |
Anti-betacellulin antibodies, their fragments, and multispecific binding molecules
|
BR112023001209A2
(pt)
|
2020-07-24 |
2023-02-14 |
Hoffmann La Roche |
Método para produzir um polipeptídeo de fusão-anticorpo-multímero
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
JP2023536340A
(ja)
|
2020-08-06 |
2023-08-24 |
ビオンテック・ソシエタス・エウロパエア |
コロナウイルスsタンパク質のための結合剤
|
WO2022040345A1
(en)
|
2020-08-18 |
2022-02-24 |
Cephalon, Inc. |
Anti-par-2 antibodies and methods of use thereof
|
AU2021331075A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
AU2021331076A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
KR20230074487A
(ko)
|
2020-08-26 |
2023-05-30 |
마렝고 테라퓨틱스, 인크. |
Trbc1 또는 trbc2를 검출하는 방법
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
JP2023539525A
(ja)
|
2020-09-02 |
2023-09-14 |
ジェンマブ エー/エス |
抗体療法
|
IL301085A
(en)
|
2020-09-10 |
2023-05-01 |
Genmab As |
A bispecific antibody against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
|
CA3190349A1
(en)
|
2020-09-10 |
2022-03-17 |
Brian Elliott |
Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
|
AU2021342566A1
(en)
|
2020-09-21 |
2023-03-02 |
Genentech, Inc. |
Purification of multispecific antibodies
|
JP2023542228A
(ja)
|
2020-09-24 |
2023-10-05 |
エフ. ホフマン-ラ ロシュ アーゲー |
遺伝子ノックアウトを有する哺乳動物細胞株
|
CA3193914A1
(en)
|
2020-10-02 |
2022-04-07 |
Louise KOOPMAN |
Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3
|
JP2023547499A
(ja)
|
2020-11-06 |
2023-11-10 |
ノバルティス アーゲー |
抗体Fc変異体
|
CA3198447A1
(en)
|
2020-11-13 |
2022-05-19 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
KR20220082775A
(ko)
|
2020-12-10 |
2022-06-17 |
주식회사 유틸렉스 |
항-pd-1 항체 및 이의 용도
|
CA3200826A1
(en)
|
2020-12-10 |
2022-06-16 |
Paul Willem Henri Ida PARREN |
Antibodies that bind gamma-delta t cell receptors
|
CN116670282A
(zh)
|
2020-12-22 |
2023-08-29 |
豪夫迈·罗氏有限公司 |
靶向xbp1的寡核苷酸
|
JP2024500512A
(ja)
|
2020-12-23 |
2024-01-09 |
イノベント バイオロジクス(シンガポール)プライベート リミティド |
抗b7-h3抗体およびその使用
|
CN114716548A
(zh)
|
2021-01-05 |
2022-07-08 |
(株)爱恩德生物 |
抗-fgfr3抗体及其用途
|
BR112023015097A2
(pt)
|
2021-01-28 |
2023-10-03 |
Janssen Biotech Inc |
Proteínas de ligação a psma e usos das mesmas
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗cd73及び抗entpd2抗体のための投与方式並びにその使用
|
MX2023009100A
(es)
|
2021-02-03 |
2023-09-25 |
Mozart Therapeutics Inc |
Agentes aglutinantes y métodos para usar los mismos.
|
JP2024512240A
(ja)
|
2021-02-18 |
2024-03-19 |
エフ. ホフマン-ラ ロシュ アーゲー |
複雑な多段階の抗体相互作用を解明するための方法
|
EP4298125A1
(en)
|
2021-02-26 |
2024-01-03 |
LAVA Therapeutics N.V. |
Antibodies that bind cd123 and gamma-delta t cell receptors
|
WO2022187591A1
(en)
|
2021-03-05 |
2022-09-09 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
MX2023010633A
(es)
|
2021-03-09 |
2023-11-28 |
Janssen Biotech Inc |
Tratamiento de canceres que carecen de mutaciones activadoras de egfr.
|
EP4314068A1
(en)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
KR20240004462A
(ko)
|
2021-04-08 |
2024-01-11 |
마렝고 테라퓨틱스, 인크. |
Tcr에 결합하는 다기능성 분자 및 이의 용도
|
EP4320444A1
(en)
|
2021-04-09 |
2024-02-14 |
F. Hoffmann-La Roche AG |
Process for selecting cell clones expressing a heterologous polypeptide
|
CA3215049A1
(en)
|
2021-04-10 |
2022-10-13 |
Baiteng ZHAO |
Folr1 binding agents, conjugates thereof and methods of using the same
|
TW202308699A
(zh)
|
2021-04-23 |
2023-03-01 |
美商普方生物製藥美國公司 |
Cd70結合劑、其結合物及其使用方法
|
TW202243689A
(zh)
|
2021-04-30 |
2022-11-16 |
瑞士商赫孚孟拉羅股份公司 |
抗cd20/抗cd3雙特異性抗體及抗cd78b抗體藥物結合物的組合治療之給藥
|
AU2021443863A1
(en)
|
2021-04-30 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
CA3214582A1
(en)
|
2021-05-07 |
2022-11-10 |
Martin SAHLIN |
Pharmaceutical compositions comprising bispecific antibodies binding to b7h4 and cd3
|
TW202309094A
(zh)
|
2021-05-18 |
2023-03-01 |
美商健生生物科技公司 |
用於識別癌症患者以進行組合治療之方法
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
CN113278071B
(zh)
|
2021-05-27 |
2021-12-21 |
江苏荃信生物医药股份有限公司 |
抗人干扰素α受体1单克隆抗体及其应用
|
JP2024522213A
(ja)
|
2021-06-14 |
2024-06-11 |
アルジェニクス ビーブイ |
抗il-9抗体及びその使用方法
|
EP4359435A1
(en)
|
2021-06-21 |
2024-05-01 |
Genmab A/S |
Combination dosage regime of cd137 and pd-l1 binding agents
|
EP4380604A1
(en)
|
2021-08-05 |
2024-06-12 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
CN113603775B
(zh)
|
2021-09-03 |
2022-05-20 |
江苏荃信生物医药股份有限公司 |
抗人白介素-33单克隆抗体及其应用
|
CN113683694B
(zh)
|
2021-09-03 |
2022-05-13 |
江苏荃信生物医药股份有限公司 |
一种抗人tslp单克隆抗体及其应用
|
AU2022339819A1
(en)
|
2021-09-03 |
2024-04-11 |
Go Therapeutics, Inc. |
Anti-glyco-lamp1 antibodies and their uses
|
TW202328188A
(zh)
|
2021-09-03 |
2023-07-16 |
美商Go治療公司 |
抗醣化-cmet抗體及其用途
|
EP4148067A1
(en)
|
2021-09-08 |
2023-03-15 |
F. Hoffmann-La Roche AG |
Method for the expression of an antibody-multimer-fusion
|
WO2023037333A1
(en)
|
2021-09-13 |
2023-03-16 |
Janssen Biotech, Inc |
CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
KR20240082388A
(ko)
|
2021-10-08 |
2024-06-10 |
추가이 세이야쿠 가부시키가이샤 |
프리필드 시린지 제제의 조제 방법
|
TW202330610A
(zh)
|
2021-10-08 |
2023-08-01 |
丹麥商珍美寶股份有限公司 |
結合至cd30及cd3之抗體
|
WO2023067138A1
(en)
|
2021-10-21 |
2023-04-27 |
LAVA Therapeutics N.V. |
Uses of gamma delta t cell activating antibodies
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
WO2023094282A1
(en)
|
2021-11-25 |
2023-06-01 |
F. Hoffmann-La Roche Ag |
Quantification of low amounts of antibody sideproducts
|
US20230183360A1
(en)
|
2021-12-09 |
2023-06-15 |
Janssen Biotech, Inc. |
Use of Amivantamab to Treat Colorectal Cancer
|
WO2023117325A1
(en)
|
2021-12-21 |
2023-06-29 |
F. Hoffmann-La Roche Ag |
Method for the determination of hydrolytic activity
|
WO2023129974A1
(en)
|
2021-12-29 |
2023-07-06 |
Bristol-Myers Squibb Company |
Generation of landing pad cell lines
|
TW202342057A
(zh)
|
2022-02-07 |
2023-11-01 |
美商健生生物科技公司 |
用於減少用egfr/met雙特異性抗體治療之患者的輸注相關反應之方法
|
US20230383010A1
(en)
|
2022-02-07 |
2023-11-30 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
WO2023174521A1
(en)
|
2022-03-15 |
2023-09-21 |
Genmab A/S |
Binding agents binding to epcam and cd137
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
TW202346337A
(zh)
|
2022-03-29 |
2023-12-01 |
美商恩格姆生物製藥公司 |
Ilt3及cd3結合劑以及其使用方法
|
TW202404637A
(zh)
|
2022-04-13 |
2024-02-01 |
瑞士商赫孚孟拉羅股份公司 |
抗cd20/抗cd3雙特異性抗體之醫藥組成物及使用方法
|
WO2023202967A1
(en)
|
2022-04-19 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
EP4285926A1
(en)
|
2022-05-30 |
2023-12-06 |
LAVA Therapeutics N.V. |
Combination treatment for chronic lymphocytic leukemia
|
WO2023232961A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
EP4292610A1
(en)
|
2022-06-15 |
2023-12-20 |
LAVA Therapeutics N.V. |
Variant antibodies that bind gamma-delta t cell receptors
|
EP4292609A1
(en)
|
2022-06-15 |
2023-12-20 |
LAVA Therapeutics N.V. |
Compositions comprising antibodies that bind gamma-delta t cell receptors
|
WO2024003837A1
(en)
|
2022-06-30 |
2024-01-04 |
Janssen Biotech, Inc. |
Use of anti-egfr/anti-met antibody to treat gastric or esophageal cancer
|
NL2032398B1
(en)
|
2022-07-06 |
2024-01-23 |
Academisch Ziekenhuis Leiden |
Bispecific antibody and uses thereof
|
WO2024028386A1
(en)
|
2022-08-02 |
2024-02-08 |
Ose Immunotherapeutics |
Multifunctional molecule directed against cd28
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024079074A1
(en)
|
2022-10-10 |
2024-04-18 |
Universite D'aix Marseille |
ANTI-sCD146 ANTIBODIES AND USES THEREOF
|
WO2024079069A1
(en)
|
2022-10-12 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Method for classifying cells
|
WO2024089551A1
(en)
|
2022-10-25 |
2024-05-02 |
Janssen Biotech, Inc. |
Msln and cd3 binding agents and methods of use thereof
|
WO2024094741A1
(en)
|
2022-11-03 |
2024-05-10 |
F. Hoffmann-La Roche Ag |
Combination therapy with anti-cd19/anti-cd28 bispecific antibody
|
WO2024110426A1
(en)
|
2022-11-23 |
2024-05-30 |
F. Hoffmann-La Roche Ag |
Method for increasing recombinant protein expression
|